Dpyd Genotyping As a Predictive Biomarker of Toxicity in Breast Cancer
نویسندگان
چکیده
منابع مشابه
Bioinformatics-based identification of miR-542-5p as a predictive biomarker in breast cancer therapy
Background Tamoxifen is the first-line hormone therapy for estrogen receptor alpha positive (ERα+) breast cancer. However, about 40% of patients with ERα + breast cancer who receive tamoxifen therapy eventually develop resistance resulting in a poor prognosis. The aim of this study was to mine available data sets in the Gene Expression Omnibus (GEO) database, including in vitro (cell lines) and...
متن کاملHGF-MET as a breast cancer biomarker
in preclinical studies, few clinical trials of MET inhibitors have demonstrated the expected therapeutic benefits. This inconsistency raises the possibilities that there are different subsets of MET/HGF-aberrant breast cancer with different responses to MET/HGF-targeted therapies and that MET inhibitors benefit only a particular subgroup of patients. To fully realize the benefits of MET inhibit...
متن کاملDown regulation of ADAM33 as a Predictive Biomarker of Aggressive Breast Cancer
Breast cancer is a heterogeneous disease with differences in its clinical, molecular and biological features. Traditionally, immunohistochemical markers together with clinicopathologic parameters are used to classify breast cancer and to predict disease outcome. Triple-negative breast cancer (TNBC) is a particular type of breast cancer that is defined by a lack of expression of hormonal recepto...
متن کاملMammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen.
Mammographic breast density has been shown to be associated with up to a 4- to 6-fold increase in risk of breast cancer, whereas tamoxifen therapy increases disease-free survival and reduces mortality. We have therefore investigated whether these effects are related. To determine the effects of tamoxifen on mammographic density, mammograms from 94 women who had received tamoxifen for breast can...
متن کاملPD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.
The resurgence of cancer immunotherapy stems from an improved understanding of the tumor microenvironment. The PD-1/PD-L1 axis is of particular interest, in light of promising data demonstrating a restoration of host immunity against tumors, with the prospect of durable remissions. Indeed, remarkable clinical responses have been seen in several different malignancies including, but not limited ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2014
ISSN: 0923-7534
DOI: 10.1093/annonc/mdu329.57